1. Lisa A. Carey, MD, on Pembrolizumab in Triple-Negative Breast Cancer

    01:13

    from Harborside Press / Added

    382 Plays / / 0 Comments

    Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discusses abstract S1-09, "A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD, of the Breast Medical Oncology Program at the University of Chicago. Time: 1:13

    + More details
    • Clifford A. Hudis, MD, FACP, on Enzalutamide in Androgen Receptor–Positive, Triple-Negative Breast Cancer

      01:47

      from Harborside Press / Added

      306 Plays / / 0 Comments

      Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract P5-19-09, “Stage 1 results from MDV3100-11: A two-stage study of enzalutamide, an androgen receptor inhibitor, in advanced androgen receptor–positive triple-negative breast cancer,” presented by Tiffany A. Traina, MD.

      + More details
      • Jame Abraham, MD, FACP, on Immunotherapy in Triple-Negative Breast Cancer

        01:53

        from Harborside Press / Added

        293 Plays / / 0 Comments

        Jame Abraham, MD, FACP, of the Cleveland Clinic, offers his thoughts on abstract S1-09, "A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.

        + More details
        • Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer

          14:16

          from Harborside Press / Added

          259 Plays / / 0 Comments

          Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Lisa Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discuss: • The TNT trial comparing docetaxel to carboplatin • The CALGB trial on response rates after neoadjuvant chemo with or without carboplatin or bevacizumab • Pembrolizumab in a phase Ib study

          + More details
          • Lisa A. Carey, MD, on the TNT Trial

            01:34

            from Harborside Press / Added

            236 Plays / / 0 Comments

            Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discusses abstract S3-01, “The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple-negative or BRCA1/2 breast cancer.”

            + More details
            • William M. Sikov, MD, on the CALGB 40603 Trial

              01:41

              from Harborside Press / Added

              205 Plays / / 0 Comments

              William M. Sikov, MD, of Women and Infants Hospital, discusses abstract S4-05, "Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709 (Alliance)."

              + More details
              • Weakening a Stubborn Breast Cancer in its Most Vulnerable Genetic Spots

                01:28

                from UT Southwestern / Added

                50 Plays / / 0 Comments

                Taking advantage of a case-rich national cancer database as well as breast cancer tissue biopsied from patients at UT Southwestern Medical Center, Stina Singel, M.D., has found that 92 percent of triple-negative breast cancers have a relatively high expression of two specific genes.

                + More details
                • Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

                  01:58

                  from Harborside Press / Added

                  43 Plays / / 0 Comments

                  Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05, “Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709,” presented by William M. Sikov, MD.

                  + More details
                  • UK Study Shows Key Enzyme Missing from Triple-Negative Breast Cancer

                    03:41

                    from reveal / Added

                    17 Plays / / 0 Comments

                    A groundbreaking new study led by the University of Kentucky Markey Cancer Center's Dr. Peter Zhou found that triple-negative breast cancer cells are missing a key enzyme that other cancer cells contain, providing insight into potential therapeutic targets to treat the aggressive cancer. Zhou's study is unique in that his lab is the only one in the country to specifically study the metabolic process of triple-negative breast cancer cells. Triple-negative breast cancer is the most deadly subtype of breast cancer and has poor clinical outcomes due to the early metastasis of tumor cells, resistance to chemotherapy, and the lack of specific drugs that target it. Produced by Research Communications at the University of Kentucky.

                    + More details
                    • The St. Gallen International Breast Cancer Conference and genetic testing for breast cancer

                      04:26

                      from Patient Power / Added

                      3 Plays / / 0 Comments

                      Renate Haidinger, a medical journalist and founding member of the German Breast Cancer Association, Brustkrebs Deutschland e.V., München, Germany, discusses the value of the St. Gallen International Breast Cancer Conference. This interview was filmed at the 14th St. Gallen International Breast Cancer Conference 2015 in Vienna, Austria.

                      + More details

                      What are Tags?

                      Tags

                      Tags are keywords that describe videos. For example, a video of your Hawaiian vacation might be tagged with "Hawaii," "beach," "surfing," and "sunburn."